185 related articles for article (PubMed ID: 37366900)
1. Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
De Simoni O; Dal Santo L; Scarpa M; Munari G; Spolverato YC; Scapinello A; Lonardi S; Soldà C; Bergamo F; Fantin A; Bardini R; Pilati P; Fassan M; Gruppo M
Curr Oncol; 2023 Jun; 30(6):5515-5528. PubMed ID: 37366900
[TBL] [Abstract][Full Text] [Related]
2. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
3. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
[TBL] [Abstract][Full Text] [Related]
4. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
[TBL] [Abstract][Full Text] [Related]
7. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy.
Liu L; Zhao G; Wu W; Rong Y; Jin D; Wang D; Lou W; Qin X
Cancer Immunol Immunother; 2016 Jan; 65(1):73-82. PubMed ID: 26646849
[TBL] [Abstract][Full Text] [Related]
8. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
[TBL] [Abstract][Full Text] [Related]
9. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golesworthy B; Wang Y; Tanti A; Pacis A; Romero JM; Cuggia A; Domecq C; Bourdel G; Denroche RE; Jang GH; Grant RC; Borgida A; Grünwald BT; Dodd A; Wilson JM; Bourque G; O'Kane GM; Fischer SE; Kron CM; Fiset PO; Omeroglu A; Foulkes WD; Gallinger S; Guiot MC; Gao ZH; Zogopoulos G
Front Oncol; 2022; 12():860767. PubMed ID: 35547873
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
[TBL] [Abstract][Full Text] [Related]
11. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
13. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
14. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
15. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
[TBL] [Abstract][Full Text] [Related]
16. [Pathological features related to onco-immunity and their clinical significance of pancreatic ductal adenocarcinoma].
Wang CM; Xu CY; Jiang S; Zhou Q; Jiang ZJ; Cheng GP; Wu MJ; Feng TT; Yin WJ
Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):419-424. PubMed ID: 35511637
[No Abstract] [Full Text] [Related]
17. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma.
Pyo JS; Son BK; Lee HY; Oh IH; Chung KH
Curr Oncol; 2021 Nov; 28(6):4367-4376. PubMed ID: 34898543
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.
Gartrell RD; Enzler T; Kim PS; Fullerton BT; Fazlollahi L; Chen AX; Minns HE; Perni S; Weisberg SP; Rizk EM; Wang S; Oh EJ; Guo XV; Chiuzan C; Manji GA; Bates SE; Chabot J; Schrope B; Kluger M; Emond J; Rabadán R; Farber D; Remotti HE; Horowitz DP; Saenger YM
Oncoimmunology; 2022; 11(1):2066767. PubMed ID: 35558160
[TBL] [Abstract][Full Text] [Related]
20. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
